State Attorneys General and Compounding Pharmacy Enforcement Actions
Several state attorneys general have opened investigations or enforcement actions against compounding pharmacies and telehealth platforms over GLP-1 marketing claims.
By the GLP Semaglutide editorial team · Last updated June 28, 2026
State attorneys general have consumer-protection authority that's separate from FDA drug regulation, and several have used it to scrutinize compounding pharmacies and telehealth platforms over marketing claims, pricing practices, or product sourcing tied to GLP-1 drugs.
How this differs from FDA action
FDA enforcement generally targets drug safety, manufacturing, and labeling; state attorney general actions more often target deceptive marketing or consumer protection law violations, meaning a company can face both types of scrutiny simultaneously for related but distinct reasons.
Where to check current actions
Individual state attorney general offices publish press releases on active enforcement actions; this is a fast-moving area best tracked through official state AG communications rather than aggregated secondary coverage.
Primary sources